A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Public ClinicalTrials.gov record NCT03849469. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Study identification
- NCT ID
- NCT03849469
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Xencor, Inc.
- Industry
- Enrollment
- 78 participants
Conditions and interventions
Conditions
- Advanced or Metastatic Solid Tumors
- Cervical Carcinoma
- Colorectal Carcinoma
- Endometrial Carcinoma
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Hepatocellular Carcinoma
- Intrahepatic Cholangiocarcinoma
- Melanoma
- Nasopharyngeal Carcinoma
- Non-small Cell Lung Carcinoma
- Pancreatic Carcinoma
- Primary Peritoneal Carcinoma
- Prostate Carcinoma
- Renal Cell Carcinoma
- Small Cell Lung Carcinoma
- Squamous Cell Anal Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Squamous Cell Penile Carcinoma
- Squamous Cell Vulvar Carcinoma
- Triple Negative Breast Cancer
- Urothelial Carcinoma
Interventions
- Pembrolizumab (Keytruda®) Biological
- XmAb®22841 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 28, 2019
- Primary completion
- Feb 15, 2023
- Completion
- Feb 15, 2023
- Last update posted
- Mar 29, 2023
2019 – 2023
United States locations
- U.S. sites
- 28
- U.S. states
- 9
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSD Medical Center - Encinitas | Encinitas | California | 92024 | — |
| Koman Family Outpatient Pavilion | La Jolla | California | 92037 | — |
| UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion) | La Jolla | California | 92037 | — |
| UCSD Altman Clinical and Translational Research Institute Building (ACTRI) | La Jolla | California | 92037 | — |
| UCSD Perlman Medical Offices | La Jolla | California | 92037 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| UCLA Hematology & Oncology Clinic | Los Angeles | California | 90095 | — |
| UC San Diego Medical Center - Hillcrest | San Diego | California | 92103 | — |
| UCSD Rancho Bernardo Medical Office | San Diego | California | 92127 | — |
| UCSD Medical Center - Vista | Vista | California | 92081 | — |
| Emory University Hospital Midtown | Atlanta | Georgia | 30308 | — |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322 | — |
| University of Iowa Hospital and Clinics | Iowa City | Iowa | 52242 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Brigham and Women's Health Care Center, Chestnut Hill | Chestnut Hill | Massachusetts | 02467 | — |
| University of Michigan Medical School | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Karmanos Cancer Institute Weisberg Cancer Treatment Center | Farmington Hills | Michigan | 48334 | — |
| Laura & Isaac Perlmutter Cancer Center at NYU Langone Health | New York | New York | 10016 | — |
| NYU Langone Medical Center (Tisch Hospital) | New York | New York | 10016 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Hospital of the University of Pennsylvania - Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania | 19104 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| UPMC Shadyside Hospital | Pittsburgh | Pennsylvania | 15232 | — |
| Mary Crowley Cancer Research - Medical City | Dallas | Texas | 75230 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Utah, Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03849469, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 29, 2023 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03849469 live on ClinicalTrials.gov.